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Introduction: Triple-negative breast cancers, particularly the claudin-low subtype, are highly aggressive and exhibit
increased tumor-initiating cell (TIC) characteristics. In this study, we demonstrate that vascular endothelial growth
factor C (VEGF-C) is highly expressed in the claudin-low breast cancer subtype and also that it mediates tumor
progression, not only through its role in lymphangiogenesis but also through regulating TIC characteristics and the
response to reactive oxygen species (ROS).
Methods: VEGF C expression was examined in breast cancer subtypes, and a VEGF C expression signature was
derived. VEGF C expression and/or its associated signature was correlated with TIC and chemoresistance signatures.
In vitro and in vivo assays were performed to determine whether VEGF-C expression alters TIC characteristics and the
response of breast cancer cells to chemotherapy and oxidative stress. Array analysis was used to identify a downstream
effector of VEGF-C, superoxide dismutase 3 (Sod3), which was tested for its involvement in VEGF-C-mediated resistance
to oxidative stress and enhancement of in vivo metastasis. The VEGF-C-associated receptor neuropilin 2 (Nrp2) was
knocked down to determine whether it is required for the observed effects of VEGF-C. Expression of VEGF C and Sod3
was assessed in human breast cancers.
Results: VEGF C is highly expressed in claudin-low breast cancers, and VEGF C and the VEGF C signature are associated
with TIC-related gene signatures. VEGF-C-knockdown in mammary carcinoma cells decreases TIC properties in vitro and
in vivo, sensitizing cells to oxidative stress and chemotherapy. We identified Sod3 as a target of VEGF-C in breast cancer
cells by demonstrating that it is required for VEGF-C-mediated cell survival in response to oxidative stress and for
VEGF-C-mediated metastasis. We demonstrate that Nrp2 is the VEGF-C-associated receptor that mediates alterations in
Sod3 expression and the response of tumor cells to oxidative stress. We show that VEGF C and Sod3 are positively
associated in human breast cancer.
Conclusions: We describe a novel mechanism by which VEGF-C contributes to metastasis via its ability to
enhance TIC-associated characteristics, particularly the response to ROS. We identified Sod3 as a critical mediator of
VEGF-C-induced metastasis, and we provide evidence that the VEGF-C–Sod3 axis plays a role in human breast cancers.* Correspondence: heide.ford@ucdenver.edu
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Reactive oxygen species (ROS) can be generated en-
dogenously or from exogenous sources. In normal cells,
ROS has important biological functions, such as in the
elimination of pathogens. However, excessive levels of
ROS can cause damage to cells, in some cases leading to
increased mutation rates. Conflicting roles, both stimu-
latory and inhibitory, have been reported for oxidative
stress in cancer progression. Cancer cells have been
shown to have increased levels of ROS, and sublethal
levels of ROS within these cells can promote proliferation
and genomic instability [1,2]. However, the increased
levels of ROS can also make cancer cells more sensitive
to ROS-inducing agents such as chemotherapeutic drugs
[3]. Thus, to survive under high-stress conditions, a
small population of cancer cells which express markers of
tumor-initiating cells (TICs) evolve a defense system
against ROS [4,5]. These data suggest that the TIC popu-
lation is protected against exogenous stress and that the
ability to withstand ROS may in part account for tumor
recurrence. Thus, understanding the mechanism by which
tumor cells acquire antioxidative capabilities, as well as
identifying means to block pathways involved in antio-
xidation, may lead to the discovery of novel therapies
that can be used in conjunction with chemotherapy or
irradiation.
Vascular endothelial growth factor C (VEGF-C) is the
major embryonic lymphangiogenic factor; it is required
for the initial migration and sprouting of committed
endothelial cells [6,7]. Overexpression of VEGF-C is ob-
served in numerous cancers [8], and its expression is
associated with high lymphatic vessel density and poor
survival [9]. A significant amount of evidence supports
an active role for VEGF-C in cancers by its induction of
tumor-associated lymphangiogenesis, which facilitates
tumor cell dissemination to lymph nodes and metastasis
to distant organs [10-12]. Interestingly, growing evidence
suggests that VEGF-C can also contribute to tumor pro-
gression in a tumor cell autonomous manner.
The effects of VEGF-C on cancer cells (as opposed to
endothelial cells) include its ability to increase tumor
cell proliferation, migration and invasion [13-17]. Cancer
cells in several tumor types are known to express one or
more of the VEGF-C-responsive receptors on the cell
surface, thereby providing a means for the growth factor
to signal directly to the cancer cells. In addition to its
effects on solid tumors, VEGF-C can promote the prolifer-
ation and survival of leukemia cells after chemotherapy
[18]. More recently, inhibition of VEGF-C was shown
to decrease mesenchymal markers and increase epi-
thelial markers, as well as to reduce the side popula-
tion (a marker of cancer stem cells) in lung cancer [19].
Together, these studies suggest that VEGF-C not only in-
duces tumor-associated lymphangiogenesis but also mightpromote tumor progression through multiple mechanisms
that either directly or indirectly affect the cancer cell.
Importantly, these studies indicate that VEGF-C may be a
potent drug target because of its ability to affect multiple
aspects of tumor progression, which encompass both the
tumor cells and cells in the tumor microenvironment.
In this study, we demonstrate that VEGF-C is import-
ant in maintaining breast TIC populations and that it
contributes to the ability of tumor cells to survive under
oxidative stress and in response to chemotherapeutic
insults. We further identify superoxide dismutase 3 (Sod3),
an antioxidant enzyme, as a downstream effector of VEGF-
C and show that it is required for the antioxidative function
of VEGF-C in vitro, as well as for the ability of VEGF-C to
mediate tumor growth and metastasis in vivo. Our results
allow us to define a novel antioxidant function for VEGF-C
in breast cancer and elucidate a novel mechanism by which
VEGF-C regulates the response to ROS.
Methods
Cell lines
To generate VEGF-C-knockdown (KD) or neuropilin 2
(Nrp2) KD in murine 66 cl4 and/or human MDA-MB-231
cells, short-hairpin RNAs (shRNAs) against VEGFC or
Nrp2 were purchased (Open Biosystems/GE Dharmacon,
Lafayette, CO, USA) and delivered retrovirally according
to the manufacturer’s protocol. Scramble shRNA obtained
from Addgene (Cambridge, MA, USA) or from Open
Biosystems/GE Dharmacon were used as controls. Cells
containing the KD constructs were selected using puro-
mycin, and the two KD clones that most efficiently re-
duced VEGF-C/Nrp2 levels were selected for subsequent
studies. Sod3 cDNA (CMV-Sport1; Open Biosystems/GE
Dharmacon) was cloned into a pCDH lentivector (SBI
System Biosciences, Mountain View, CA, USA) and trans-
fected into 66 cl4 VEGF-C KD cells. Stable clones with
Sod3 restoration were selected via green fluorescent pro-
tein sorting. The pCDH lentivector was also introduced
into the 66 cl4 scramble and VEGF-C KD cells to serve as
a control. The mouse mammary carcinoma 66 cl4 cell line
was kindly provided by Dr. Fred R. Miller, and the MDA-
MB-231 cell line was fingerprinted by the University
of Colorado Cancer Center DNA sequencing center
to ensure that it matched the authentic MDA-MB-231
cell line (November 2011; American Type Culture Collec-
tion, Manassas, VA, USA).
In vitro cell-based assays
Annexin V apoptosis assays (BD Biosciences, San Jose, CA,
USA) and ALDEFLUOR assays (STEMCELL Technologies,
Vancouver, BC, Canada) were performed according to the
manufacturers’ protocols. In cell viability assays (Molecu-
lar Probes/Life Technologies, Eugene, OR, USA), 66 cl4
scramble and VEGF-C KD cells were plated at 106 cells
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H2O2 (1 mM) or H2O (control) in serum-free medium for
24 hours. Attached cells and cells in the medium were col-
lected and stained using ethidium homodimer 1 dye for
dead cells and calcein AM dye for live cells. The percent-
age of live and dead cells within the populations was ana-
lyzed by flow cytometry. In chemosensitivity assays,
cells were plated at 25,000 cells per well (5 replicate
wells) in 96-well plates. The following day, cells were
treated with varying concentrations of etoposide
(Sigma-Aldrich, St Louis, MO, USA) or doxorubicin
(Sigma-Aldrich) in serum-free media. After 24 hours,
cell viability was assessed using the CellTiter-Glo assay
(Promega, Madison, WI, USA). For clonogenic assays,
1,000 cells per well were plated in triplicate in 6-well
plates. The following day, cells were treated with doxoru-
bicin or phenethyl isothiocyanate (PEITC) in serum-free
media. After 24 hours, cells were washed and fresh medium
(with complete serum) was added. After 2 weeks, colonies
were stained with crystal violet and counted visually.
Real-time PCR
All analyses were performed using the CFX96 real-time
PCR detection system (Bio-Rad Laboratories, Hercules,
CA, USA). TaqMan primers used against mouse and
human VEGFC were purchased from Applied Biosystems
(Foster City, CA, USA), and TaqMan primer against
mouse Nrp2 was purchased from Integrated DNA Tech-
nologies (Coralville, IA, USA). The SYBR Green assay
primers for Sod3 were as follows: murine Sod3, forward:
GCTCTTGGGAGAGCCTGAC, and reverse: GGTCAA
GCCTGTCTGCTAGG; human SOD3, forward: CAGGA
GAGAAAGCTCTCTTGGA, and reverse: GAGCAGGC
AGGAACACAGTAG. Relative expression was normalized
to the expression of cyclophilin B in the cells. A mouse oxi-
dative quantitative PCR array was purchased (QIAGEN,
Valencia, CA, USA) and analyzed according to manufac-
turer’s instructions.
Western blot analysis
Whole-cell lysates were collected with radioimmunopre-
cipitation assay buffer, and medium from cells was con-
centrated using a centrifugal filter unit (EMD Millipore,
Billerica, MA, USA). VEGF-C and Sod3 antibodies (sc-
25783 and sc-67089, respectively) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
body against human SOD3 was obtained from Novus
Biologicals (NBP1-22417; Littleton, CO, USA). Antibody
against NRP2 was obtained from Cell Signaling Technology
(D39A5; Danvers, MA, USA).
In vivo experiments
Six- to eight-week-old female BALB/c mice were pur-
chased from the National Cancer Institute (Rockville, MD,USA). For the orthotopic experiment, 1 × 106 cells in
100 μl of Dulbecco’s modified Eagle’s medium were
injected into the fourth mammary fat pad. Tumor growth
was measured weekly using calipers, and in vivo imaging
was performed weekly as previously described [20]. Ani-
mal protocols performed in this study were approved by
the Institutional Animal Care and Use Committee at the
University of Colorado Anschutz Medical Campus.
Statistical analysis
Statistical analyses were performed by two-tailed t-test
for comparing two groups. One-way analysis of variance
(ANOVA) with Tukey’s posttests were performed for
comparing more than three groups. Two-way ANOVA
with Bonferroni posttests were performed for tumor
growth and cell viability analyses. χ2 and Fisher’s exact
tests were performed for tumor formation analyses noted
in the figure legends. GraphPad Prism 5 software (Graph-
Pad Software, La Jolla, CA, USA) was used to perform
the analyses. Error bars represent the standard error
of the mean of three independent experiments. Aster-
isks denote significant differences from control groups
(*P < 0.05; **P < 0.01; ***P < 0.001).
Results
VEGF C expression is high in the claudin-low subtype of
breast cancer and correlates with gene expression
signatures associated with poor clinical outcome
We previously found that VEGF-C KD in 66 cl4 mouse
mammary carcinoma cells not only influences distant
metastasis when these cells are orthotopically injected
into immune competent mice, but also, surprisingly,
decreases the primary tumor size [20]. These data sug-
gested to us that VEGF-C may play a role outside its
normally described role in lymphangiogenesis, because
lymphangiogenesis is believed to serve as a route for me-
tastasis but has not been shown to correlate with tumor
growth. Although VEGF C expression has been widely
demonstrated to correlate with lymph node status and
poor prognosis, its expression in specific subtypes of
breast cancer has not been extensively examined. Exam-
ination of VEGF C expression in the Neve et al. cell line
microarray data set [21,22] revealed that, in contrast to
its highly related family member VEGFD, VEGF C is
expressed predominantly in basal B breast cancer cell
lines (Figure 1A). Basal B breast cancer cells have been
shown to display mesenchymal/stem cell–like character-
istics and to be more invasive in vitro [22,23], and they
are considered to be most closely related to the claudin-
low intrinsic subtype of human breast cancer [24]. The
claudin-low subtype of breast cancer is similarly charac-
terized by stem cell and epithelial-to-mesenchymal tran-
sition (EMT)–like features and, most importantly,
correlates with a poor prognosis [24,25]. Analysis of two
Figure 1 Vascular endothelial growth factor C mRNA expression in human breast cancer cell lines and breast tumors. (A) Box plots of
VEGFC and VEGFD gene expression across 51 previously reported breast cancer cell lines grouped into basal A, basal B and luminal subgroups
(left). Vascular endothelial growth factor C (VEGF C) expression in human breast cancer cell lines was assessed using GOBO [21]. (B) Gene
expression data from 337 and 855 human breast tumors (UNC337 and UNC855). Log2-transformed and median centered gene expression values
for VEGF C across the intrinsic subtypes, including basal, claudin-low (CL), human epidermal growth factor receptor 2 (HER2)-enriched (HER2),
luminal A (A), luminal B (B) and normal-like (N-L) breast tumors. (C) Pearson’s correlation values for each gene signature compared to each other
for 337 human breast tumors (UNC337 data set). Color scale bars represent Pearson’s correlations: r =1 (red), r = 0 (black) and r = −1 (green).
DMFS, distant metastasis free survival. MS, mammosphere.
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prise 337 and 855 breast tumor samples, respectively
[24,27], demonstrates that enriched VEGF-C mRNA
expression occurs in the claudin-low subtype of breast
tumors compared to all other subtypes (Figure 1B). The
majority of claudin-low tumors (61% to 71%) fall into the
clinical classification of triple-negative breast cancers
[24], which lack expression of the estrogen receptor
(ER), the progesterone receptor (PR) and the human
epidermal growth factor receptor 2 (HER2), and are
aggressive cancers that confer poor clinical outcomes.
Because triple-negative breast cancers do not have
higher levels of lymphangiogenesis than other breastcancer subtypes [28,29], these data support the hy-
pothesis that expression of VEGF-C may mediate ag-
gressive phenotypes outside its effect on lymphatic
vessel growth.
On the basis of the observation that VEGF C is
predominately expressed in the claudin-low subtype of
breast cancer, which is known to have TIC features, we
next sought to determine whether VEGF C expression
correlates with a TIC or cancer stem cell signature previ-
ously created using CD44+/CD24− expression [30,31].
Indeed, VEGF C expression was found to correlate
with the CD44+/CD24-low + mammosphere (MS)
signature (Pearson’s r = 0.61) (Figure 1C) [31] and,
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in breast tumors after chemotherapy (Pearson’s r = 0.51)
(Figure 1C) [32].
Although the function of VEGF-C has been studied
extensively, the broader gene expression programs that
mediate its function have not been elucidated fully. To
identify the genes that most strongly parallel VEGF C
expression, Pearson’s correlation values were identified
for VEGF C and each gene that was present in a panel of
human breast cancer cell lines [33] and tumors [34].
In total, 13 genes had positive Pearson’s correlation
values >0.5, indicating that these genes exhibit similar
gene expression profiles (VEGF C-13 signature) (Additional
file 1: Figures S1A and S1B). We found that this signature,
like VEGF C alone, was expressed predominantly in the
claudin-low subtype of breast cancer in two different data
sets (Additional file 1: Figures S1C and S1D). Interestingly,
our newly derived VEGF C-13 signature is more strongly
correlated with CD44+/CD24 low +MS and chemore-
sistance signatures (r = 0.75 and r = 0.79, respectively)
than VEGF C alone, indicating that broader gene ex-
pression profiles are more efficient than single genes
in capturing biological programs. We further found
that the VEGF C-13 signature also correlates with gene
sets associated with shortened metastasis-free survival
(r = 0.58) [30] (Figure 1C). Thus, our data suggest that
VEGF C and its related signature are strong indicators of
aggressive subtypes of breast cancer and of poor clinical
outcomes. They further suggest that VEGF-C may drive
not only a lymphangiogenic program but also a program
associated with TICs.
VEGF C expression is enriched in TIC and is necessary to
maintain ALDH-positive TIC population
In breast cancer, TICs are thought to make up a small
proportion of the cells within a tumor; however, import-
antly, they have been shown to have the ability to self-
renew, to establish new tumors and to contribute to
tumor heterogeneity. Because we observed that VEGF C
expression correlates with a breast TIC-related signa-
ture, we reasoned that VEGF-C may play a functional
role in promoting breast cancer TICs. Analysis of micro-
array data sets obtained from clinical patient breast tu-
mors [31] demonstrated that VEGF-C mRNA is enriched
in tumorspheres formed from cells of primary breast tu-
mors compared to that in the bulk tumors (Figure 2A).
Similarly, we detected enrichment in the expression of
VEGF C in tumorspheres formed from multiple breast
cancer cell lines compared to expression in their adherent
counterparts (Figure 2B and Additional file 2: Figure S2).
Together, these data suggest that expression of VEGF C
may contribute to TIC characteristics in breast cancer
cells. To assess whether VEGF-C influences TIC popu-
lations, we performed fluorescence-activated cell sortinganalysis for the aldehyde dehydrogenase (ALDH)–positive
population, whose activity is used as a surrogate marker
for TICs [35], in breast cancer cells with or without
VEGF-C KD. Figure 2C shows a significant decrease in
ALDH-positive cells in 66 cl4 VEGF-C KD cells compared
to the control KD cells (Figure 2D) (Additional file 3:
Figure S3). We performed VEGF-C KD in an additional
cell line, MDA-MB-231, a basal B human breast can-
cer cell line that highly expresses VEGF-C receptors
(Additional file 4: Figure S4) [14], and, similarly, we ob-
served that the ALDH-positive population was signifi-
cantly decreased (Figure 2D). These results suggest that
VEGF-C expression may be important in maintaining the
breast TIC population.
VEGF-C knockdown leads to decreased tumor initiation
and growth in vivo, but does not affect proliferation or
apoptosis
We next examined the effect of VEGF-C on in vivo
breast tumor initiation. Using our previously established
66 cl4-scramble control (scram) and 66 cl4-VEGF-C KD
cells (Additional file 4: Figure S4) [20], ten cells of each
cell line were injected into the left and right abdominal
mammary fat pads of immunocompetent BALB/c mice
(as shown in Figure 3A). At week 9, we observed that
mammary fat pads injected with 66 cl4-scram cells formed
tumors with 87.5% efficiency (7/8), whereas VEGF-C KD
cells formed tumors with only 37.5% efficiency (3/8)
(*P = 0.038, χ2 test) (Figure 3A). In addition, tumors
that arose in the context of 66c14-VEGF-C KD were
significantly smaller and grew less compared to 66 cl4-
scram tumors over time (Figure 3B), which is similar to
what we had previously observed when higher cell num-
bers were injected [20]. Despite the dramatic difference in
size between 66 cl4-scram and 66 cl4-VEGF-C KD
tumors, we did not observe significant alterations in pro-
liferation or apoptosis between these cells in vitro or
in vivo (Figures 3C to 3E). Together, our findings suggest
that VEGF-C affects tumor initiation and growth through
increasing the TIC population in breast cancer.
VEGF-C protects breast cancer cells from oxidative stress
and compounds generating reactive oxygen species
Because VEGF-C expression correlates with gene sets that
are enriched in TICs and upregulated in breast tumors after
chemotherapy (Figure 1), we examined whether VEGF-C
confers resistance to commonly used chemotherapeutic
agents in breast cancer cells. Analysis of microarray data
sets showed that breast cancer cell lines that are resistant to
chemotherapeutic drugs [36,37], specifically etoposide
and doxorubicin, express higher levels of VEGF C than
cell lines that are sensitive to these drugs (Additional
file 5: Figure S5A). Indeed, we found that VEGF-C KD
sensitizes 66 cl4 cells to doxorubicin and etoposide
Figure 2 Vascular endothelial growth factor C–knockdown decreases the aldehyde dehydrogenase–positive tumor-initiating cell
population. (A) Expression of vascular endothelial growth factor C (VEGF-C) mRNA in bulk tumors or tumorspheres formed from cells of primary
breast tumors. Gene expression levels were obtained from public microarray data sets [31]. (B) Expression of VEGF-C in attached parental cells or
tumorspheres formed by growing 66 cl4 cells in serum-free suspension conditions. Pictures of attached cells and tumorspheres are shown.
(C) Representative flow cytometric data in an ALDEFLUOR assay. Diethylaminobenzaldehyde (DEAB) is a specific inhibitor of aldehyde dehydrogenase
(ALDH), which was used as a gating control. (D) Quantification of the ALDH-positive population in scramble control (scr) and VEGF-C KD lines from
66 cl4 and MDA-MB-231 cells. Data were combined from three independent experiments using one scramble KD and two VEGF-C KD (KD 1 and 2)
cell lines for both 66 cl4 and MDA-MB-231 cells.
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these findings using a clonogenic assay and further
tested the effect of another compound, PEITC, which is
a natural compound from cruciferous vegetables that
harbors both chemopreventive and chemotherapeutic
activities and which has been shown to cause cancer cell
death, specifically by disrupting antioxidant systems
[3,38,39]. Both doxorubicin and PEITC treatment sig-
nificantly decreased the ability of 66 cl4 cells to formcolonies when VEGF-C was knocked down, as com-
pared to scramble control KD cells (Figure 4A and B).
Chemotherapies are known to induce DNA damage in
part by increasing cellular redox levels, and TICs are
thought to have enhanced antioxidant pathways. Thus, we
next investigated whether VEGF-C may protect breast
cancer cells from oxidative stress. Induction of oxidative
stress via treatment with a high concentration of H2O2
(1 mM) led to a significant increase in cell death and a
Figure 3 (See legend on next page.)
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Figure 3 Vascular endothelial growth factor C–knockdown in 66 cl4 mouse mammary carcinoma cells decreases tumor growth and
tumor formation in vivo. (A) Tumor formation efficiency of ten cells from 66 cl4-scram and 66 cl4-VEGF-C KD1/2 cells injected into the left and
right mammary fat pads of female BALB/c mice. The experiment was ended at week 9 after injection because of the large primary tumor sizes in
the control group. scr, Scramble; VEGF-C KD, Vascular endothelial growth factor C knockdown. (B) Representative picture of 66 cl4-scram and
66 cl4-VEGF-C KD1 and KD2 tumors derived from the left and right mammary fat pads of the same animal (left). Tumor growth in the mice was
measured using calipers and calculated using the formula V = 1/2(W)(W)(L) (right). *P < 0.05; **P < 0.01. (C) Representative flow data show results of a
bromodeoxyuridine (BrdU) assay performed on 66 cl4-scram cells, as well as on VEGF-C KD1 and KD2 cells, combined as KD1/2 (left). BrdU-positive
populations from 66 cl4-scram and VEGF-C KD1/2 cells at 0, 24 and 48 hours after release from serum starvation are shown. Data were quantified from
two independent experiments with duplicates in the control and two different short-hairpin RNA cell lines. (D) Representative flow data from a
fluorescein isothiocyanate-annexin V apoptosis assay (left). Quantification of the apoptosis assay is shown from two independent experiments
with duplicates for detection of the early and late apoptotic populations in the 66 cl4-scram and VEGF-C KD1 and KD2 cells (data combined as KD1/
KD2). PI, Propidium Iodide. (E) Quantification of mitotic and apoptotic cells is shown from 66 cl4-scram and 66 cl4-VEGF-C KD tumors. Mitotic and
apoptotic cells were counted in ten high-power fields per hematoxylin and eosin–stained section. Three control and three VEGF-C KD tumors were
counted and analyzed in total. Ave, Average.
Figure 4 Inhibition of vascular endothelial growth factor C sensitizes 66 cl4 mammary carcinoma cells to oxidative stress and to
chemotherapeutic agents. (A) Inhibition of vascular endothelial growth factor C (VEGF-C) in 66 cl4 cells decreases colony formation in the
presence of doxorubicin (Dox). (B) Inhibition of VEGF-C in 66 cl4 cells decreases colony formation in the presence of phenethyl isothiocyanate
(PEITC). Representative quantification (of three independent experiments) is shown for the number of colonies formed in 66 cl4-scram and
VEGF-C KD1/KD2 cells (top). Representative pictures of colonies formed in 66 cl4-scram and VEGF-C KD cells treated with doxorubicin (3 μM) or
PEITC (1 μM) or the corresponding vehicle control (Ctrl; bottom). (C) Representative flow data show the staining of live (calcein AM dye) and dead
(ethidium homodimer (EthD) 1 dye) cell populations in 66 cl4-scram and VEGF-C KD cells treated with control (H2O) or H2O2 (1 mM) (left).
Quantification of dead cells from 66 cl4-scram and 66 cl4-VEGF-C KD1/KD2 cells treated with control and put under oxidative stress (combination
of three independent experiments).
Wang et al. Breast Cancer Research 2014, 16:462 Page 8 of 17
http://breast-cancer-research.com/content/16/6/462
Wang et al. Breast Cancer Research 2014, 16:462 Page 9 of 17
http://breast-cancer-research.com/content/16/6/462decrease in cell viability when VEGF-C was knocked down
in 66 cl4 cells (Figure 4C and Additional file 6: Figure S6).
A similar result was observed in MDA-MB-231 breast can-
cer cells in which VEGF-C was knocked down (Additional
file 7: Figure S7). These results suggest an important func-
tion of VEGF-C in protecting mammary carcinoma cells
from oxidative stress or chemotherapy-induced cell death,
implying that inhibition of VEGF-C may be a potential ad-
juvant therapy in combination with ROS-generating che-
motherapeutic drugs in the treatment of breast cancers.
Superoxide dismutase 3 is regulated by VEGF-C
To elucidate the mechanism by which VEGF-C contrib-
utes to cell survival in the face of oxidative stress in
breast cancer cells, we performed a quantitative PCR
array to determine whether any genes related to oxidative
stress were altered by VEGF-C. We identified 9 genes of
the 84 examined that were regulated (up or down) twofold
or more in response to VEGF-C KD (Figure 5A). Sod3
(which encodes extracellular Sod3 and plays a crucial role
in scavenging superoxide) was found to have the highestFigure 5 Vascular endothelial growth factor C regulates Sod3 express
66 cl4-scramble and 66 cl4-VEGF-C KD2 cells was converted to cDNA and u
genes of the eighty-four examined were identified in the PCR array with m
expression was determined using a real-time PCR SYBR Green assay on 66
analysis of Sod3 expression in 66 cl4-scram and VEGF-C KD1 and KD2 cells
SYBR Green assay on three pairs of 66 cl4-scram and VEGF-C KD1 or KD2 tuand most consistent differences in expression between the
66c14-scramble and 66 cl4-VEGF-C KD cells (Figure 5B),
and the regulation of Sod3 by VEGF-C was also confirmed
in MDA-MB-231 cells (Additional file 8: Figure S8). We
also examined the levels of Sod3 in 66 cl4-scram and
VEGF-C KD tumors that developed in the left and right
abdominal mammary fat pads of the same mice. De-
creased Sod3 expression was detected in three different
VEGF-C KD tumors compared to the corresponding
scramble control tumors (Figure 5C). Together, our re-
sults demonstrate that VEGF-C regulates Sod3.
Restoration of Sod3 expression partially rescues
phenotypes mediated by VEGF-C
To determine whether Sod3 mediates the ability of
VEGF-C to act as an antioxidant, we reintroduced Sod3
into VEGF-C KD cells (using KD2 from Figure 5B) to
levels similar to those observed in the scramble control
cells (Figure 6A). In addition, the scramble control and
VEGF-C KD cells were transfected with an empty vector
to serve as a control. We confirmed the functionality ofion in 66 cl4 mammary carcinoma cells. (A) Total RNA from
sed to perform a mouse oxidative stress PCR array. Nine candidate
ore than a twofold change in response to VEGF-C KD. (B) Sod3 mRNA
cl4-scram and 66 cl4-VEGF-C KD1 and KD2 cells (top). Western blot
(bottom). (C) Sod3 mRNA expression was determined by real-time PCR
mors (each pair was derived from the same animal).
Figure 6 (See legend on next page.)
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Figure 6 Restoration of Sod3 in 66 cl4-VEGF-C KD cells partially rescues resistance to oxidative stress and tumor progression. (A)
Expression of Sod3 in 66 cl4-VEGF-C KD cells (KD2 in Figure 5). Empty vector was also introduced into 66 cl4-scram and 66 cl4-VEGF-C KD2 cells
as a control. Sod3 expression was assessed in each cell line using a real-time PCR SYBR Green assay (top). Expression of secreted Sod3 in the
media of 66 cl4-scram, 66 cl4-VEGF-C KD and 66 cl4-VEGF-C KD + Sod3 cells was measured by Western blot analysis (bottom). (B) Flow cytometry
was performed to measure cell death induced by H2O2 under each condition shown. Three independent experiments were performed, and the
data were combined for quantitation. (C) Cells from the 66 cl4-scram, VEGF-C KD and VEGF-C KD + Sod3 lines were injected into the fourth
mammary fat pad of female BALB/c mice. Tumor growth in the mice was measured using calipers and calculated using the formula V = 1/2(W)(W)(L)
(top). A representative picture of tumors from each group shows that restoration of Sod3 in VEGF-C KD cells partially rescues the size of tumors
compared to scramble control tumors (bottom). (D) Representative in vivo image of 66 cl4-scram, VEGF-C KD and VEGF-C KD + Sod3 groups at day
60 after injection (top). Quantitation of bioluminescence imaging (in photons per second) emanating from the region surrounding the lungs (bottom).
Mice that did not develop primary tumors were excluded from the quantitation. (E) Incidence of tumor formation and metastasis in the groups of
mice injected with 66 cl4-scram, VEGF-C KD or VEGF-C KD + Sod3 cells. Restoration of Sod3 expression in the VEGF-C KD cells increased the
number of mice that developed primary tumors and metastases, although not to the levels observed in the scramble control group. Fisher’s
exact test (two-sided) results indicated a significant increase in the number of mice that developed metastases when Sod3 expression was
restored in the VEGF-C KD tumors.
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rescues cell death induced by oxidative stress almost as
efficiently as the antioxidant N-acetylcysteine (NAC)
(Figure 6B). To determine whether restoration of Sod3
in the VEGF-C KD cells could rescue tumor progression,
we injected luciferase labeled 66 cl4-scramble control,
66 cl4-VEGF-C KD and 66 cl4-VEGF-C Sod3 restored
(VEGF-C KD + Sod3) cell lines into immunocompetent
female BALB/c mice, and tumor growth and metastases
were measured. We observed that reexpression of Sod3
in the VEGF-C KD cells restored their ability to grow
and metastasize in vivo compared to VEGF-C KD cells
(Figure 6C and D). In addition, when total numbers of
mice with tumors and/or metastases were counted, we
observed that VEGF-C KD resulted in a significant de-
crease in the number of mice that developed primary
tumors and metastases in response to orthotopic in-
jections and that restoration of Sod3 in VEGF-C KD
cells trended toward rescuing the number of mice in
which primary tumors formed and significantly rescued
the number of mice that developed metastases (Figure 6E).
Our results demonstrate a critical role for Sod3 down-
stream of VEGF-C in mediating tumor progression.
Nrp2 regulates Sod3 expression and response of
mammary carcinoma cells to oxidative stress
Reexpression of VEGF-C-associated receptors on tumor
cells has been observed, which suggests autocrine regu-
lation of tumor cells by VEGF-C. Indeed, studies provide
evidence that VEGF-C-related receptors mediate aggres-
sive phenotypes of tumor cells [8,14,40]. To further in-
vestigate which of the known VEGF-C receptors may
mediate the increase in Sod3 expression and the antioxi-
dant phenotype, we first determined the expression of
the receptors in 66 cl4 mammary carcinoma cells. Cor-
roborating a previous finding [41], 66 cl4 cells primarily
expressed Nrp2 and had undetectable levels of VEGF
receptor 3 (VEGFR3) (Additional file 9: Figure S9). Exam-
ination of the Neve et al. cell line microarray data set[21,22] revealed that NRP2 expression tracks similarly to
VEGF C expression, as both are expressed predominantly
in basal B breast cancer cell lines (Figure 7A, left). In con-
trast, VEGFR3 is not enriched in any specific subtype of
breast cancer cell lines (Figure 7A, right). Thus, to deter-
mine whether NRP2 is the relevant receptor for VEGF-C
in this system, we asked whether Nrp2 KD could recapitu-
late VEGF-C KD. Indeed, knockdown of Nrp2 in the
66 cl4 mammary carcinoma cell line (Figure 7B) led to a
significant decrease in Sod3 expression compared to
control KD cells (Figure 7B and Additional file 10:
Figure S10). Importantly, knockdown of Nrp2 sensitized
66 cl4 mammary carcinoma cells to oxidative stress–in-
duced cell death (Figure 7C), similar to what we observed
with VEGF-C KD. The fact that Nrp2 (a known receptor
for VEGF-C) loss phenocopies VEGF-C loss strongly sug-
gests that VEGF-C acts through Nrp2 to mediate changes
in Sod3 levels and the response to oxidative stress.
VEGF C and SOD3 are positively correlated in human
cancers
To determine whether VEGF-C regulates SOD3 in human
cancers, we examined whether their expression correlates
in tumors. Interestingly, we found that expression of
VEGFC and SOD3 positively correlate not only in breast
cancer (using two different human data sets) [42] (Bittner
Multi-cancer data set, unpublished data, 1 January 2006)
but also in kidney and cervical cancers (Bittner Multi-
cancer data set) (Figure 8A and Additional file 11:
Figure S11). Thus, these data further support our find-
ings and suggest that the relationship between VEGF-C
and Sod3 is relevant to human tumors.
Discussion
In genomic studies, researchers have identified five major
breast cancer intrinsic subtypes, including luminal A and B,
HER2-positive, basal and claudin-low. Claudin-low breast
cancers constitute about 7% to 14% of all molecular sub-
types. These tumors show EMT gene expression profiles,
Figure 7 (See legend on next page.)
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Figure 7 Neuropilin 2–knockdown in 66 cl4 mouse mammary carcinoma cells decreases superoxide dismutase 3 expression and
sensitizes cells to oxidative stress. (A) NRP2 and VEGFR3 mRNA expression in human breast cancer cell lines. Box plots of NRP2 (left) or VEGFR3
(FLT4) (right) gene expression across 51 previously reported breast cancer cell lines grouped into basal A, basal B and luminal subgroups. NRP2
and VEGFR3 gene expression in human breast cancer cell lines was assessed using GOBO [21]. (B) Two different short-hairpin RNAs (shRNAs 1 and
2) were used to knock down neuropilin 2 (Nrp2) in 66 cl4 cells. Expression of Nrp2 in 66 cl4-scram and 66 cl4-Nrp2 knockdown (KD) cells was
determined by Western blot analysis (left). Decreased expression of superoxide dismutase 3 (Sod3) was observed in 66 cl4-Nrp2 KD cells compared to
66 cl4-scram cells (right). Whole-cell lysates (top) or media (bottom) from 66 cl4-scram and 66 cl4-Nrp2 KD cells were collected for the detection of
Sod3 by Western blotting. (C) Viability of 66 cl4-scram and 66 cl4-Nrp2 KD cells treated with increasing doses of H2O2. A CellTiter-Glo assay was used to
measure viable cells. Three independent experiments were performed and combined for quantification.
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differentiated than the other subtypes of breast cancer [24].
Claudin-low breast cancers are highly aggressive, and the
majority of the tumors lack hormone (ER and PR) and
HER2 expression. Thus, patients harboring this subtype ofFigure 8 Expression of VEGFC and SOD3 in human cancers. (A) VEGFC
microarray data set [43] (as indicated in the figure) and were plotted by ex
correlation (two-tailed). (B) Proposed model for the function of vascular endo
of VEGF-C in a subset of tumor cells confers the ability to resist oxidative stres
Sod3. However, VEGF-C mediates other pathways that are important in confe
Blocking VEGF-C signaling would therefore be expected to sensitize breast ca
reduction in tumor-initiating cells (TICs) and to decrease lymphangiogenesis,breast cancer have a poorer prognosis, in part due to the
lack of targeted therapies. In this study, we analyzed micro-
array data sets and demonstrate for the first time that
VEGF C expression is high in the more aggressive subtypes
of breast cancer (basal B and claudin-low), both in cell linesand SOD3 expression values were retrieved from an Oncomine
pression value. Statistical analysis was performed using Pearson r
thelial growth factor C (VEGF-C) in breast cancer progression. Expression
s generated during tumor growth, and this ability is partially mediated by
rring resistance to chemotherapies, thus contributing to tumor recurrence.
ncers to chemotherapies that induce oxidative stress, to contribute to a
thus likely improving survival and prevent recurrence.
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lymphatic density and/or invasion is not more commonly
observed in the more aggressive subtypes of breast cancer
[28,29,44,45], implying that high VEGF-C expression may
confer alternate roles in mediating tumor aggressiveness
in the claudin-low subtype. Because higher frequencies of
TICs are found in these poorly differentiated types of
breast cancers, we investigated whether VEGF-C corre-
lates with a cancer stem cell signature in human breast
cancer. In addition to analyzing how VEGF-C itself corre-
lates with different tumor-related gene expression signa-
tures, we created a VEGF C-13 gene signature and found
that this gene set correlates with signatures which have
been implicated in poor clinical outcome, including cancer
stemness and chemoresistance, and that it correlates with
a gene signature which is associated with shortened time
to metastasis. These data imply that high VEGF-C expres-
sion in breast cancer may contribute to tumor progression
by mediating a TIC-like phenotype, therapy resistance and
metastasis.
Families of growth factors or cytokines, such as fibroblast
growth factor or interleukin 6, respectively, are known to
play a role in maintaining and/or expanding cancer stem-
like populations through autocrine or paracrine signaling
[46,47]. The VEGF family has been studied extensively with
respect to its role in the development of the vasculature
and/or lymphatic system. In contrast, very few studies have
implicated VEGF family members in the regulation of
TIC properties. Recently, the results of some studies
have pointed to a role for the receptors of VEGF family
members in cancer stem-like properties through autocrine
signaling pathways. For example, the VEGFR2 axis was
shown to promote the viability and growth of glioma stem-
like cells, and NRP2 has been implicated in breast tumor
initiation [40,48]. A previous study demonstrated that
VEGF-C levels are enriched in TICs isolated from breast
cancer lesions and from the MCF7 breast carcinoma cell
line [49], and we extend these findings to demonstrate for
the first time a functional role for VEGF-C in the regula-
tion of breast TIC populations both in vitro and in vivo.
Taken together with our finding that levels of VEGF-C are
elevated in claudin-low breast cancers, our data suggest
that high VEGF-C may be important in maintaining the
TIC population in the claudin-low subtype of breast can-
cer, which is known to have prevalent TIC features.
Our study also provides evidence that VEGF-C mediates
additional characteristics associated with TICs, such as
modulating antioxidant responses and chemoresistance.
Conventional radiation and therapeutic agents are known
to cause DNA damage and apoptosis in tumors at least in
part by generating oxidative stress. In a heterogeneous
tumor, a small population of cells, the TIC population, is
thought to enhance antiredox systems which allow them
to survive after chemotherapy [5], thereby accounting fordisease recurrence. Indeed, residual breast cancer cells
isolated from patients who have received conventional ther-
apy exhibit stem cell-like features and express increased
antioxidant enzymes [4,5,31]. Because we observed that
VEGF-C KD decreased TIC populations, we asked whether
VEGF-C expression may also be involved in the response
to oxidative stress in breast cancer cells. In support of our
findings in breast cancer, VEGF-C was recently implicated
in the response to ROS in prostate cancer cell lines [50].
Our data demonstrate that VEGF-C does protect breast
cancer cells from ROS-induced cell death. Importantly, we
identify, for the first time to our knowledge, an antioxidant
factor—Sod3—as a downstream effector of VEGF-C. We
show that Sod3 is at least in part responsible for the ability
of VEGF-C to protect against ROS-induced cell death and
to mediate breast tumor progression.
The superoxide dismutase family contains three mem-
bers (Sod1, Sod2 and Sod3) that protect cells and/or tis-
sues against intracellular or extracellular ROS damage.
However, the role of Sod family members has not been
well studied in cancer, and where it has been studied,
the roles are controversial. For example, studies exist
that show a protective role for Sod3 against chemical or
hormone-induced tumor formation [51,52]. In contrast,
other studies have demonstrated that expression of Sod2
maintains the metabolic activity of cancer cells when
they are detached from the extracellular matrix and that
it increases tumor promotional nuclear factor (NFκB)
signaling [53,54]. In our present study, we demonstrate a
tumor promotional effect of Sod3 downstream of VEGF-
C in that restoration of Sod3 in the VEGF-C KD cells
not only partially rescues tumor growth but also rescues
metastasis. However, since Sod3 is not sufficient to fully
rescue the in vivo tumor growth and/or metastasis in
response to VEGF-C KD (Figure 6), nor is it sufficient
to rescue chemoresistance after VEGF-C KD in vitro
(Additional file 12: Figure S12), other pathways and/or
factors downstream of VEGF-C must be required to
fully restore these phenotypes. Given the results of our
ROS array, it is possible that VEGF-C stimulates antioxi-
dant effects via regulating several redox-related enzymes
and that, though Sod3 is a major regulator of the ROS
response downstream of VEGF-C, it is not the only one. It
is also possible that VEGF-C confers TIC-related chemo-
resistance via mediating additional signaling pathways
(such as Wnt/β-catenin, Notch or NFκB signaling) [55].
Furthermore, because VEGF-C can also promote metasta-
sis through its ability to mediate lymphangiogenesis, and
because VEGF-C expression in tumor cells can affect the
infiltration of immune cells [56,57], multiple functions of
VEGF-C are likely required to mediate its full effects on
tumor progression and metastasis.
On the basis of our results, we propose a novel model,
shown in Figure 8B. VEGF-C expression in a small
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functions during tumor progression. In part, VEGF-C
promotes tumor progression via regulating Sod3, which
can eliminate the excessive oxidative species generated
when tumor cells are rapidly growing. However, other
pathways downstream of VEGF-C, not limited to Sod3
regulation, are involved in the ability of cells to survive
chemotherapy. Thus, blocking VEGF-C may be useful
in combination with chemotherapeutic drugs (especially
with those known to induce ROS) to increase treatment
efficacy, because inhibition of VEGF-C may decrease
the TIC population, sensitize cells to oxidative stress–
induced cell death and affect the tumor microenviron-
ment by decreasing lymphangiogenesis.
Conclusions
We have uncovered a novel mechanism for the vascular
endothelial growth factor, VEGF-C, in regulating tumor
rather than lymphatic endothelial cells. We show, for the
first time to our knowledge, that VEGF-C is highly
expressed in the aggressive claudin-low subtype of breast
cancer, and we further demonstrate that VEGF-C expres-
sion correlates with TIC and chemoresistant signatures.
Our data demonstrate that high VEGF-C expression leads
to an increase in the TIC population, an altered cellular
response to ROS and an increase in resistance to chemo-
therapy, all likely contributing to its ability to enhance
tumor progression. We uncover a novel mechanism by
which VEGF-C regulates the response to oxidative stress,
via regulation of Sod3 expression. Importantly, Sod3
downstream of VEGF-C is required for tumor growth and
metastasis in the mammary orthotopic xenograft model,
providing evidence that VEGF-C mediates breast cancer
metastasis in part through regulating ROS. Our results
suggest that inhibition of VEGF-C may suppress TIC-like
phenotypes and sensitize breast tumors to chemotherapy
in the claudin-low subtype, for which few targeted therap-
ies currently exist.
Additional files
Additional file 1: Figure S1. Generation of the VEGFC-13 gene
signature and the expression of VEGFC-13 gene signature in breast
tumors. (A) Scatterplot of Pearson’s correlation values for VEGFC and all
genes within the UNC35 cell line database and UNC288 tumor database.
Red box denotes 13 genes with Pearson’s correlations >0.5 with VEGFC in
both data sets. The VEGFC gene signature was identified by utilizing two
data sets generated from Agilent two-color gene expression arrays
(Agilent Technologies, Santa Clara, CA, USA). For the human breast tumor
data set, 288 tumors representing all of the intrinsic subtypes were used
(UNC288). For the human breast cancer cell line data set, 35 distinct
human breast cancer cell lines (UNC35), also representing each subtype,
were utilized [33,34]. For both data sets, data were retrieved from the
UNC MicroArray Database. To identify Pearson’s correlation values, genes
were median-centered, and all genes that were strongly correlated with
VEGFC (>0.5) across all samples in both data sets were selected. (B) Table
of genes correlated with VEGFC expression in both the UNC35 cell linedatabase and the UNC288 tumor database. (C) and (D) Box-and-whisker
plots show the expression of the VEGFC signature (VEGFC-13) in the UNC
337 and UNC855 tumor data sets.
Additional file 2: Figure S2. Expression of VEGFC in attached parental
cells or tumorspheres. MDA-MB-468, MDA-MB-231 and T47D human
breast cancer cells were grown under attached conditions or formed by
growing cells in serum-free suspension conditions. Real-time PCR was
performed, and VEGFC relative expression was determined after
normalization to cyclophilin gene expression in the cells.
Additional file 3: Figure S3. Expression of VEGFC in 66 cl4-scramble
and 66 cl4-VEGF-C-knockdown cells. VEGFC gene expression was
detected by real-time PCR using the TaqMan assay. Two different shRNAs
against VEGFC were delivered to the 66 cl4 cells, and stable knockdown
cells were selected using puromycin.
Additional file 4: Figure S4. VEGF-C is efficiently knocked down in
MDA-MB-231 breast cancer cells. (A) Expression of VEGFC in the human
MDA-MB-231 breast cancer cell line. Real-time PCR (TaqMan assay) was
performed to determine relative expression of VEGFC in MDA-MB-231
compared to MCF7 or human dermal lymphatic endothelial cells
(HDLECs). (B) Expression of VEGF-C in MDA-MB-231 control KD (NS) and
two VEGF-C knockdown cells determined by Western blot analysis.
β-actin was used as a loading control.
Additional file 5: Figure S5. VEGF-C knockdown sensitizes 66 cl4
mammary carcinoma cells to chemotherapeutic agents. (A) Expression of
VEGFC mRNA levels in breast cancer cell lines that are sensitive (including
intermediate levels of sensitivity) or resistant to etoposide or doxorubicin
were retrieved from the Garnett cell line and Györffy cell line data sets in
Oncomine [36,37]. (B) 66 cl4-scram and VEGF-C KD cell viability in
response to different doses of etoposide or doxorubicin measured by
CellTiter-Glo assay. Data from two VEGF-C KD cells were combined for
quantification. Three independent experiments were performed.
Additional file 6: Figure S6. Viability of 66 cl4-scram and 66
cl4-VEGF-C KD cells treated with increasing doses of H2O2. Luciferase
activity of the cells was measured using in vivo imaging as an indicator of
cell viability. As shown by quantifying the luciferase signal, VEGF-C KD
sensitizes cells to H2O2-induced cell death, and cell viability can be
restored by cotreatment with NAC, a strong antioxidant.
Additional file 7: Figure S7. Viability of MDA-MB-231 control KD and
two VEGF-C KD cells treated with increasing doses of H2O2. Cell viability
was measured using the CellTiter-Glo assay, a luminescent detection of
ATP in viable cells. Two independent experiments were performed on
control cell lines and two different VEGF-C KD cell lines.
Additional file 8: Figure S8. VEGF-C regulates SOD3 expression in
MDA-MB-231 breast cancer cells. Sod3 protein expression was determined
by Western blot analysis in MDA-MB-231 scram control cells and two
VEGF-C KD cell lines. β-actin was used as a loading control.
Additional file 9: Figure S9. Expression of VEGF-C receptors in 66 cl4
mammary carcinoma cells. Real-time PCR analysis was performed to
determine the relative expression of VEGFR3 and NRP2 in 66 cl4 cells.
NMuMG cells were used as a positive control for the expression of
VEGFR3. 67NR is isogenic to 66 cl4, but is nonmetastatic (whereas 66 cl4
is metastatic). Expression of VEGFR3 and NRP2 was determined and
plotted after normalization to cyclophilin expression (Ppib) in the cells.
Additional file 10: Figure S10. Sod3 mRNA expression in 66 cl4-Nrp2-
knockdown cells. Real-time PCR analysis was performed to determine the
relative expression of Sod3 in 66 cl4 control and Nrp2 KD cells. Expression
of Sod3 was determined and plotted after normalization to cyclophilin
(Ppib) expression in the cells.
Additional file 11: Figure S11. Expression of VEGFC and SOD3 in human
cancers. VEGFC and SOD3 expression values were retrieved from an Oncomine
microarray data set (Bittner Multi-cancer data set) and were plotted by expression
value. Statistical analysis was performed using Pearson r correlation (two-tailed).
Additional file 12: Figure S12. Restoration of Sod3 in VEGF-C KD cells
is not sufficient to rescue the ability of 66 cl4 cells to resist doxorubicin
and PEITC-induced cell death. Viability of 66 cl4-scram, VEGF-C KD and
VEGF-C KD + Sod3 cells treated with doxorubicin and PEITC as measured
using in vivo imaging for luciferase activity as an indicator of cell viability.
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